Patents by Inventor John Hatcher

John Hatcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220130417
    Abstract: An apparatus is described that comprises a microphone array and a plurality of transducers. The microphone array and the plurality of transducers are communicatively coupled with at least one processor. The apparatus includes the microphone array for receiving at least one signal. Each transducer of the plurality of transducers is configured to deliver a correction signal along a transducer beam spread axis, wherein the plurality of transducers is positioned on the apparatus for providing a combined transducer beam spread coverage in the horizontal plane. One or more applications running on the at least one processor use information of the at least one signal to detect a sound event. The detecting the sound event includes selecting transducers from the plurality of transducers and instructing the selected transducers to deliver a correction signal.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 28, 2022
    Inventors: Richard Seltzer, Jonathan William Huber, Paul Case, John Hatcher
  • Patent number: 11248007
    Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: February 15, 2022
    Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
  • Patent number: 11238889
    Abstract: An apparatus is described that comprises a microphone array and a plurality of transducers. The microphone array and the plurality of transducers are communicatively coupled with at least one processor. The apparatus includes the microphone array for receiving at least one signal. Each transducer of the plurality of transducers is configured to deliver a correction signal along a transducer beam spread axis, wherein the plurality of transducers is positioned on the apparatus for providing a combined transducer beam spread coverage in the horizontal plane. One or more applications running on the at least one processor use information of the at least one signal to detect a sound event. The detecting the sound event includes selecting transducers from the plurality of transducers and instructing the selected transducers to deliver a correction signal.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 1, 2022
    Assignee: Radio Systems Corporation
    Inventors: Richard Seltzer, Jonathan William Huber, Paul Case, John Hatcher
  • Publication number: 20210361774
    Abstract: Disclosed are bifunctional compounds (degraders) that target LRKK2 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the degraders to treat neurodegenerative diseases and disorders such as Parkinson's disease and brain cancer (e.g., gliomas and glioblastomas).
    Type: Application
    Filed: October 16, 2019
    Publication date: November 25, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • Publication number: 20210347772
    Abstract: Disclosed are compounds that possess inhibitory activity against LRRK2. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders including neurodegenerative diseases and disorders such as Parkinson's disease, and brain cancer (e.g., gliomas and glioblastomas).
    Type: Application
    Filed: October 16, 2019
    Publication date: November 11, 2021
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., VORONOI INC.
    Inventors: Nathanael S. Gray, John Hatcher, Jieun Choi, Hwanguen Choi, Eunhwa Ko, Namdoo Kim
  • Publication number: 20210340102
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: June 15, 2021
    Publication date: November 4, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John Hatcher, Nathanael S. Gray, Hwangeun Choi, Pasi Janne, Tinghu Zhang
  • Publication number: 20210230144
    Abstract: The present invention relates to heterobifunctional compounds (degraders), compositions and methods for treating diseases or conditions mediated by Interleukin Receptor-Associated Kinases (IRAKs).
    Type: Application
    Filed: February 13, 2019
    Publication date: July 29, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • Patent number: 11066363
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: July 20, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John Hatcher, Nathanael S. Gray, Hwangeun Choi, Pasi Janne, Tinghu Zhang
  • Publication number: 20210115055
    Abstract: Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 22, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher, Hwan Geun Choi
  • Patent number: 10975055
    Abstract: The present invention provides novel compounds of Formula (I?), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: April 13, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang, John Hatcher, Sara Jean Buhrlage
  • Publication number: 20210054020
    Abstract: The present application provides bifunctional compounds of Formula (Ia): (Ia), or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties for one or mor of cyclin-dependent kinase 8 (CDK8) and cyclin-dependent kinase 19 (CDK19). The present application also relates to methods for the targeted degradation of CDK8 and/or CDK19 through the use of the bifumtional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 and/or CDK19 which can be utilized in the treatment of disorders modulated by CDK8 and/or CDK19.
    Type: Application
    Filed: February 13, 2019
    Publication date: February 25, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • Patent number: 10913744
    Abstract: Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: February 9, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher, Hwan Geun Choi
  • Publication number: 20210027801
    Abstract: An apparatus is described that comprises a microphone array and a plurality of transducers. The microphone array and the plurality of transducers are communicatively coupled with at least one processor. The apparatus includes the microphone array for receiving at least one signal. Each transducer of the plurality of transducers is configured to deliver a correction signal along a transducer beam spread axis, wherein the plurality of transducers is positioned on the apparatus for providing a combined transducer beam spread coverage in the horizontal plane. One or more applications running on the at least one processor use information of the at least one signal to detect a sound event. The detecting the sound event includes selecting transducers from the plurality of transducers and instructing the selected transducers to deliver a correction signal.
    Type: Application
    Filed: July 25, 2019
    Publication date: January 28, 2021
    Inventors: Richard Seltzer, Jonathan William Huber, Paul Case, John Hatcher
  • Publication number: 20200385405
    Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: March 8, 2018
    Publication date: December 10, 2020
    Applicants: Cornell University, Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, David A, Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
  • Publication number: 20200369715
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof are provided and methods involving compounds of Formula (I) as effective inhibitors of CDK8 and/or CDK19 are also provided.
    Type: Application
    Filed: February 13, 2019
    Publication date: November 26, 2020
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, John Hatcher
  • Publication number: 20200299257
    Abstract: The present invention provides novel compounds of Formula (I?), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma)), inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as an interleukin-1 receptor-associated kinase (IRAK) (e.g., IRAKI and/or IRAK4) in the subject.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 24, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Tinghu Zhang, John Hatcher, Sara Jean Buhrlage
  • Publication number: 20200223798
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Application
    Filed: October 30, 2019
    Publication date: July 16, 2020
    Inventors: John HATCHER, Nathanael S. GRAY, Hwan Geun CHOI, Pasi JANNE, Tinghu ZHANG
  • Patent number: 10711036
    Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 14, 2020
    Assignees: Cornell University, Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Spandan Chennamadhavuni, Ari M. Melnick, Lorena Fontan Gabas, Hao Wu, Qi Qiao, Guangyan Du
  • Patent number: 10689366
    Abstract: Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: June 23, 2020
    Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.
    Inventors: Ari M. Melnick, Lorena Fontan Gabas, Nathanael S. Gray, David A. Scott, John Hatcher, Guangyan Du
  • Publication number: 20190389904
    Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT, lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).
    Type: Application
    Filed: August 26, 2016
    Publication date: December 26, 2019
    Applicants: Cornell University, Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Spandan Chennamadhavuni, Ari M. Melnick, Lorena Fontan Gabas, Hao Wu, Qi Qiao, Guangyan Du